SynthesisFrontiers in pharmacology2025
Shoutai pills for treating recurrent miscarriage: a systematic review and meta-analysis of the safety and clinical efficacy in 11 randomized controlled trials.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Potential Role of MicroRNA-410-5p and BIRC7 Gene Pathways in Recurrent Miscarriage in an Egyptian Population.Molecular biology reports · 2026Article
- Therapeutic effect and anti-inflammatory mechanism of modified Shoutai pills against lipopolysaccharide-induced miscarriage in mice.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite centuries of empirical use in Traditional Chinese Medicine (TCM) for miscarriage prevention, Shoutai Pills lack comprehensive scientific validation to support their widespread clinical application. Current evidence regarding their safety profile remains limited. Methods: Following PRISMA guidelines, we conducted a systematic review of randomized controlled trials (RCTs) from PubMed, Embase, Cochrane Library, CNKI, and Wanfang up to October 2024. Eligible studies evaluated Shoutai Pills as monotherapy or adjunctive treatment for recurrent miscarriage, reporting outcomes including safety (adverse events), live birth rate, pregnancy retention rate, TCM syndrome scores, and serum D-dimer levels. Meta-analyses were performed using random-effects or fixed-effect models, with heterogeneity assessed via I Results: Eleven RCTs (n = 888 participants) met inclusion criteria. No significant difference in overall adverse events between groups (RR = 0.91, 95% CI: 0.53-1.57; p = 0.74; I Conclusion: Shoutai Pills show promise as a safe and effective complementary therapy for recurrent miscarriage, significantly improving pregnancy outcomes and symptom relief.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.